In addition, the pan-FGFR inhibitor Erdafitinib, used in combination with fulvestrant and palbociclib, is currently under evaluation in a phase I clinical study to assess the anti-tumor activity in patients with ER+/HER2-/FGFR-amplified metastatic breast cancer (NCT03238196). This evidence concerns the gene ERBB2 and neoplasm.